US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

18.91

-0.0800-0.42%

Post-market: 18.910.00000.00%16:29 EDT

Volume:470.22K

Turnover:8.86M

Market Cap:2.47B

PE:10.70

High:18.96

Open:18.94

Low:18.66

Close:18.99

52wk High:22.24

52wk Low:14.34

Shares:130.62M

Float Shares:126.13M

Volume Ratio:1.05

T/O Rate:0.37%

Dividend:0.96

Dividend Rate:5.08%

EPS(TTM):1.77

EPS(LYR):1.05

ROE:8.78%

ROA:0.95%

PB:0.91

PE(LYR):17.95

Loading ...

Overview Company News Filings

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

Press Release: CARsgen Therapeutics Announces 2025 Interim Results

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Press Release: The Metals Company Announces Second Quarter 2025 Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

Immatics Announces Second Quarter 2025 Financial Results and Business Update

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Immunocore reports second quarter financial results and provides a business update

Provident Bank Names Michael a. Perito Svp, Head of Corporate Strategy

THOMSON REUTERS

Provident Bank Names Michael A. Perito SVP, Head of Corporate Strategy

Royalty Pharma Reports Second Quarter 2025 Results

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

TMC Releases Two Economic Studies with Combined NPV of $23.6B and Declares World-First Nodule Reserves

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PFS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":18.91,"timestamp":1761681600000,"preClose":18.99,"halted":0,"volume":470224,"hourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:29 EDT","volume":30021,"amount":567697.11,"timestamp":1761683347172},"delay":0,"floatShares":126131374,"shares":130624153,"eps":1.766905,"marketStatus":"Closed","change":-0.08,"latestTime":"10-28 16:00:00 EDT","open":18.94,"high":18.96,"low":18.66,"amount":8863473.7669,"amplitude":0.015798,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.766905,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761724800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":18.99,"dividendRate":0.050767,"preHourTrading":{"tag":"盘前","latestPrice":18.9,"preClose":18.99,"latestTime":"08:53 EDT","volume":75,"amount":1417.5,"timestamp":1761656031342},"postHourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:29 EDT","volume":30021,"amount":567697.11,"timestamp":1761683347172},"volumeRatio":1.052293,"impliedVol":0.1839,"impliedVolPercentile":0.372},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126131374,"roa":"0.95%","roe":"8.78%","lyrEps":1.053397,"volumeRatio":1.052293,"shares":130624153,"dividePrice":0.96,"high":18.96,"amplitude":0.015798,"preClose":18.99,"low":18.66,"week52Low":14.335,"pbRate":"0.91","psRate":"3.00","week52High":22.24,"institutionHeld":0.6972,"latestPrice":18.91,"eps":1.766905,"divideRate":0.050767,"volume":470224,"delay":0,"ttmEps":1.766905,"open":18.94,"prevYearClose":18.87,"prevWeekClose":18.99,"prevMonthClose":19.28,"prevQuarterClose":19.28,"fiveDayClose":18.68,"twentyDayClose":19.28,"sixtyDayClose":18.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-10-29","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":0.55,"defaultRemindTime":1761768000000,"name":null,"time":"Post Market","dateTimestamp":1761710400000,"actualEps":null},{"date":"2025-08-15","symbol":"PFS","amount":0.24,"announcedDate":"2025-07-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-15","defaultRemindTime":1755264600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-15","currency":"USD","dateTimestamp":1755230400000,"payDate":"2025-08-29"},{"market":"US","date":"2025-07-24","symbol":"PFS","fiscalQuarterEnding":"2025/06","expectedEps":0.5,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753329600000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"},{"executeDate":"2016-11-10","recordDate":"2016-11-15","paymentDate":"2016-11-30","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-10-27","current":10.70233,"percent":0.472334,"low":6.410614,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"high":33.979783,"avg":13.531229,"sd":6.392284,"marketCap":2480552665},"quantilePoints":[{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-18","current":16.4974,"twenty":8.954399,"median":10.718159,"eighty":16.928687,"marketCap":2432888120},{"date":"2025-07-25","current":10.379214,"twenty":8.954399,"median":10.725223,"eighty":16.928687,"marketCap":2396954859},{"date":"2025-08-01","current":10.305683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2379973707},{"date":"2025-08-08","current":10.124683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2338173949},{"date":"2025-08-15","current":10.899581,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2517127428},{"date":"2025-08-22","current":10.633738,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2455734076},{"date":"2025-08-29","current":11.255924,"twenty":8.954399,"median":10.756738,"eighty":16.928687,"marketCap":2599420644},{"date":"2025-09-05","current":11.380362,"twenty":8.954068,"median":10.786944,"eighty":16.930946,"marketCap":2628157958},{"date":"2025-09-12","current":11.312487,"twenty":8.954399,"median":10.806309,"eighty":16.928687,"marketCap":2612483060},{"date":"2025-09-19","current":11.493487,"twenty":8.954399,"median":10.823106,"eighty":16.928687,"marketCap":2654282788},{"date":"2025-09-26","current":11.0523,"twenty":8.984755,"median":10.848771,"eighty":16.928687,"marketCap":2552395949},{"date":"2025-10-03","current":11.018362,"twenty":8.984755,"median":10.865282,"eighty":16.928687,"marketCap":2544558500},{"date":"2025-10-10","current":10.876956,"twenty":8.984755,"median":10.902195,"eighty":16.928687,"marketCap":2511902462},{"date":"2025-10-17","current":10.113363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2335559855},{"date":"2025-10-24","current":10.475363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2419159313},{"date":"2025-10-27","current":10.741206,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2480552665}],"updateTime":1761704280928},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562724163","title":"Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724163","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562724163?lang=en_us&edition=fundamental","pubTime":"2025-08-28 02:43","pubTimestamp":1756320180,"startTime":"0","endTime":"0","summary":"Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/27/Konskie--Poland---December-08--2024-Summ.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/27/Konskie--Poland---December-08--2024-Summ.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47367794/summit-akeso-report-lung-cancer-survival-boost-with-ivonescimab-a-rival-to-mercks-keytruda-multi-billion-dollar-franchise-says-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47367794/summit-akeso-report-lung-cancer-survival-boost-with-ivonescimab-a-rival-to-mercks-keytruda-multi-billion-dollar-franchise-says-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["MRK","IE00BLSP4452.SGD","IE0009355771.USD","LU1934455277.USD","IE000M9KFDE8.USD","LU1934455863.HKD","LU0070302665.USD","BK4534","LU0122379950.USD","SG9999014542.SGD","SG9999001176.USD","LU0203347892.USD","LU1162221912.USD","BK4550","SG9999014575.USD","LU0203345920.USD","LU0238689110.USD","LU1929549753.HKD","LU1585245621.USD","LU1069347547.HKD","SMMF","SG9999001440.SGD","IE00BJJMRZ35.SGD","SG9999015341.SGD","LU1989772923.USD","LU0320765489.SGD","LU0098860793.USD","LU1917777945.USD","OS","PFS","IE00B1BXHZ80.USD","LU1066051225.USD","LU0266013472.USD","LU1699723380.USD","LU1093756168.USD","IE00BN8TJ469.HKD","LU1941712348.USD","SG9999014567.USD","LU1974910355.USD","BK4007","LU2361044865.SGD","IE00B4R5TH58.HKD","IE00BLSP4239.USD","IE00BFTCPJ56.SGD","LU1035773651.USD","IE00BBT3K403.USD","LU1116320737.USD","LU2023250504.SGD","LU1057294990.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2562746623","title":"Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2562746623","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562746623?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:05","pubTimestamp":1756296300,"startTime":"0","endTime":"0","summary":"Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) PatientsFLORHAM PARK, N.J., Aug.  27, 2025  (GLOBE NEWSWI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139982/29076/en/Cellectar-Biosciences-to-Present-Data-in-Oral-Session-and-Panel-Discussions-at-the-American-Association-for-Cancer-Research-Special-Conference-on-Discovery-and-Innovation-in-Pediat.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","CNS","PFS","BK4135","BK4117","BK4107","AFG","OS","BK4097","BK4139","BK4195","BK4211","DHG"],"gpt_icon":0},{"id":"2560665188","title":"European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2560665188","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560665188?lang=en_us&edition=fundamental","pubTime":"2025-08-18 21:10","pubTimestamp":1755522600,"startTime":"0","endTime":"0","summary":"OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug.  18, 2025  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/18/3135068/0/en/European-Commission-Grants-Approval-of-OGSIVEO-nirogacestat-for-the-Treatment-of-Adults-with-Desmoid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4156","BK4211","PFS","EC","BK4225","BK4201","BK4203","HR","BK4195"],"gpt_icon":0},{"id":"2559099543","title":"Press Release: CARsgen Therapeutics Announces 2025 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559099543","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559099543?lang=en_us&edition=fundamental","pubTime":"2025-08-15 08:15","pubTimestamp":1755216900,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results.-- Cash and bank balances were around RMB1,261 million as of June 30, 2025.Cash and cash equivalents and deposits at the end of 2025 are expected to. be not less than RMB1,100 million. We expect to have adequate cash into. been completed in more than 20 provinces or cities. CARsgen has received. areas such as hematologic malignancies, solid tumors, and autoimmune. Cash and bank balances were around RMB1,261 million as of June 30, 2025, representing a decrease of around RMB218 million from around RMB1,479 million as of December 31, 2024. The decrease was mainly due to the payment of research and development expenses, administrative expenses and investment of capital expenditur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK1585","BK0183","BK4232","R","PCL","BK4022","03160","02171","BK0209","BK4211","LU1223082519.USD","BK0196","LU1223082196.USD","BK4007","CDE","BK4230","BK1574","CAR","LU2328871848.SGD","BK4195","SLE","LU1223083913.SGD","BK0132","BK4588","BK4604","OS","TM","LENZ","LU1969619763.USD","BK4539","BK1587","BK0187","BK4585","BK4139","BK4077","BK0175","BK4555","BK4017","BK4097","BK1161","000963","PFS","BK4099"],"gpt_icon":0},{"id":"2559296109","title":"IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559296109","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559296109?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:05","pubTimestamp":1755201900,"startTime":"0","endTime":"0","summary":"Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (pembrolizumab) for the treatment of first-line advanced melanoma, but statistic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133859/0/en/IO-Biotech-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","LU0208291251.USD","LU1917777945.USD","SG9999014559.SGD","LU0211331839.USD","LU1069347547.HKD","LU1162221912.USD","LU2023250504.SGD","LU2028103732.USD","LU0266013472.USD","IE0002141913.USD","LU2324357040.USD","LU0098860793.USD","LU1548497426.USD","LU1057294990.SGD","LU1720051017.SGD","LU1732800096.USD","IOBT","LU0122379950.USD","BK4195","LU0234570918.USD","BK4127","IE00BSNM7G36.USD","BK4534","LU1061106388.HKD","LU2133065610.SGD","LU0058720904.USD","LU1074936037.SGD","LU1929549753.HKD","IE000M9KFDE8.USD","SG9999015358.SGD","LU2361044949.HKD","IE00BZ1G4Q59.USD","PFS","LU1989772923.USD","LU1244550221.USD","LU0265550359.USD","IE00BYTNYN87.SGD","LU1035773651.USD","LU0234572021.USD","LU1732799900.SGD","BK4565","LU0070302665.USD","LU1066051811.HKD","LU1244550577.SGD","BK4139","BK4585","01698","LU0912757837.SGD"],"gpt_icon":1},{"id":"2559196164","title":"Press Release: The Metals Company Announces Second Quarter 2025 Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559196164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559196164?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:01","pubTimestamp":1755201660,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug. 14, 2025  -- TMC the metals company Inc.  , a leading developer of the world's largest estimated undeveloped resource of critical metals essential to energy, defense, manufacturing and infrastructure, today provided a corporate update and second quarter results for the period ending June 30, 2025.-- Total cash of approximately $115.8 million at June 30, 2025. -- $10.6 million cash used in operations for the quarter ended June 30, 2025. -- Operating loss of $22 million, net loss of $74.3 million and net loss per. share of $0.20 for the quarter ended June 30, 2025. NOAA Confirms Full Compliance of TMC USA's Exploration License Applications. -- On August 11, 2025, TMC USA received notice of full compliance from the. National Oceanic and Atmospheric Administration  on its exploration. applications, and reconfirmation that TMC USA has priority right over. Hard Minerals Resources Act  as the Company targets Q4 2027. TMC Releases Two Economic Studies with Combined NPV of $23.6B","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","TMC","BK4563","BK4168","IRR","NPV","PFS","BK4195"],"gpt_icon":0},{"id":"2559957671","title":"24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559957671","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559957671?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:05","pubTimestamp":1755173100,"startTime":"0","endTime":"0","summary":"Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug.  14, 2025  (GLOBE NEWSWIRE) -- 247marketnews.co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133445/0/en/24-7-Market-News-LIXTE-Biotech-Advances-Precision-Oncology-Pipeline-with-Multiple-Phase-1B-2-Trial-Readouts-Expected-in-2H-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4195","PFS","BK4113","BK4211","MSS"],"gpt_icon":0},{"id":"2559954840","title":"Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954840","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954840?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:19","pubTimestamp":1755170340,"startTime":"0","endTime":"0","summary":"Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Onc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133335/29076/en/Cellectar-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU2413666426.HKD","CLRB","LU1892829315.USD","LU1974910355.USD","LU2362540622.SGD","LU2355687059.USD","BK4097","LU0289960550.SGD","LU0069063385.USD","LU0689626769.HKD","LU0472753341.HKD","LU1712237335.SGD","LU2229751404.USD","LU2125910336.SGD","BK4120","LU2238339852.HKD","BK4589","BK4135","LU0057025933.USD","LU1430594728.SGD","LU2106854487.HKD","EMA","BK4211","LU0347712357.USD","CMA","BK4588","LU2023250843.SGD","OS","LU2125910179.SGD","CNS","BK4139","LU2041044095.USD","LU1923621640.USD","LU2362541513.USD","LU2240825500.USD","LU1939255532.USD","LU0289961442.SGD","LU2211814178.USD","BK4566","LU1917777945.USD","BK4081","BK4585","LU0124676726.USD","LU1585245621.USD","LU2092937221.SGD","PFS","WM","LU2362541273.HKD","LU0289739343.SGD"],"gpt_icon":0},{"id":"2559260604","title":"BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2559260604","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559260604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:00","pubTimestamp":1755086400,"startTime":"0","endTime":"0","summary":"ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed(Cell Press) Publication with MD Anderson Collaboration highl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132541/0/en/BeyondSpring-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update-Accelerates-Momentum-with-Promising-Clinical-Advances-and-Strategic-Leadership-Appointment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PFS","BK4211","OS","DC","BYSI","BK4195","ORR","BK4017","BK4097"],"gpt_icon":0},{"id":"2559360471","title":"Immatics Announces Second Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559360471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559360471?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:00","pubTimestamp":1755082800,"startTime":"0","endTime":"0","summary":"Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132422/0/en/Immatics-Announces-Second-Quarter-2025-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","INN","OS","PFS","BK4139","BK4195","BK4211","BK4218","BK4181","IMTX","ORR"],"gpt_icon":0},{"id":"2559509624","title":"ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559509624","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559509624?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029100,"startTime":"0","endTime":"0","summary":"– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132107/0/en/ALX-Oncology-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00BMG7P819.SGD","BK4211","BK4195","IE00BD4GTT62.SGD","BK4080","CEI","IE00BMG7P702.HKD","ALX","BK4182","TRP","ORR","IE00BMG7P694.USD","IE00BMG7P926.USD","OS","PFS","IE00BD4GTV84.USD","BK4213","IE00BD4GTW91.USD","BK4097","IE00BMG7P587.USD","BK4231","BK4144"],"gpt_icon":0},{"id":"2558650505","title":"Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558650505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558650505?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:00","pubTimestamp":1754913600,"startTime":"0","endTime":"0","summary":"- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130826/0/en/Theriva-Biologics-Reports-Second-Quarter-2025-Operational-Highlights-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211","BK4097","OS"],"gpt_icon":0},{"id":"2558652634","title":"Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2558652634","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558652634?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:00","pubTimestamp":1754910000,"startTime":"0","endTime":"0","summary":"In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130767/0/en/Compass-Therapeutics-Reports-2025-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4139","BK4539","BK4211","OS","BTC","BK4007","CMPX","LENZ","BK4097"],"gpt_icon":0},{"id":"2558579382","title":"Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558579382","media":"Benzinga","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558579382?lang=en_us&edition=fundamental","pubTime":"2025-08-09 01:23","pubTimestamp":1754673832,"startTime":"0","endTime":"0","summary":"Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/08/47008723/genmab-abbvie-partnered-blood-cancer-combination-drug-cuts-risk-of-disease-progression-by-79","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445239.USD","LU1066051811.HKD","PFS","LU0256863811.USD","BK4007","LU0345770993.USD","IE00B42XCP33.USD","LU0070302665.USD","LU1674673691.USD","LU1023059063.AUD","IE00B3T34201.USD","JNJ","SG9999015986.USD","BK4566","ABBV","LU0122379950.USD","LU0345769128.USD","LU1066053197.SGD","BK4109","GMAB","LU1732800096.USD","LU2129689605.HKD","BK4532","NVS","IE00BJT1NW94.SGD","LU0466842654.USD","LU0203345920.USD","LU1935042991.SGD","LU0640476718.USD","BK4550","LU0208291251.USD","LU2237443978.SGD","LU0689472784.USD","ORR","LU0058720904.USD","LU0456855351.SGD","LU1037948541.HKD","LU1074936037.SGD","LU1267930573.SGD","ASH","LU2463526074.USD","LU0029864427.USD","LU1196500208.SGD","LU1718418525.SGD","LU0234570918.USD","LU0211331839.USD","FL","LU1989772840.SGD","LU2089984988.USD","LU2237443382.USD"],"gpt_icon":0},{"id":"2557935563","title":"Immunocore reports second quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557935563","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557935563?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:00","pubTimestamp":1754564400,"startTime":"0","endTime":"0","summary":"KIMMTRAK (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Ph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129043/0/en/Immunocore-reports-second-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU0347712357.USD","IE00B19Z4B17.USD","LU2065731478.USD","BK4207","ATOM","IE00B66KJ199.SGD","OS","IE00B7SZL793.SGD","LU2413666699.HKD","BK4121","CM","LU1721428933.USD","CRS","PROC","LU1878469433.USD","BK4533","LU0963586101.USD","BK4599","ALT","MTD","PFS","BK4139","IE00BFXG0V08.USD","BK4006","LU1093756168.USD","BK4588","BK4007","BK4548","BK4567","LU2413666426.HKD","LU1093756325.SGD","BK4147","LU2211817866.USD","IE00BYQQ9H92.USD","BK4195","BK4211","IE0031619046.USD","CTA","BK4585","ORR"],"gpt_icon":0},{"id":"2557719393","title":"Provident Bank Names Michael a. Perito Svp, Head of Corporate Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2557719393","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557719393?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:00","pubTimestamp":1754481601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA4Z60WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4211","PFS","BK4195"],"gpt_icon":0},{"id":"2557037104","title":"Provident Bank Names Michael A. Perito SVP, Head of Corporate Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2557037104","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557037104?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:00","pubTimestamp":1754481600,"startTime":"0","endTime":"0","summary":"New Position to Spearhead Bank's Long-Term Growth and Market AlignmentISELIN, N.J., Aug.  06, 2025  (GLOBE NEWSWIRE) -- Provident Bank,a leading New Jersey-based financial institution, has announced t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128265/0/en/Provident-Bank-Names-Michael-A-Perito-SVP-Head-of-Corporate-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","STRK","BK4596","BK4585","BK4516","BK4195","BK4211","BK4588","BK4023","PFS","BK4595"],"gpt_icon":1},{"id":"2557376762","title":"Royalty Pharma Reports Second Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376762","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376762?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:00","pubTimestamp":1754478000,"startTime":"0","endTime":"0","summary":"Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128201/0/en/Royalty-Pharma-Reports-Second-Quarter-2025-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4093","EC","OS","PFS","BK4195","BK4211","CF","CV","BK4201","SOFR","BK4082","BK4588","BK4585"],"gpt_icon":0},{"id":"2557966883","title":"Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557966883","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557966883?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:30","pubTimestamp":1754393400,"startTime":"0","endTime":"0","summary":"- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug.  05, 2025  (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Na","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127236/0/en/Sensei-Biotherapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4585","L","BK4588","BK4211","LU0053666078.USD","BK4107","PFS","SNSE"],"gpt_icon":0},{"id":"2556322386","title":"TMC Releases Two Economic Studies with Combined NPV of $23.6B and Declares World-First Nodule Reserves","url":"https://stock-news.laohu8.com/highlight/detail?id=2556322386","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556322386?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:00","pubTimestamp":1754305200,"startTime":"0","endTime":"0","summary":"TMC published two technical economic assessments prepared in accordance with Subpart 1300 of Regulation S-K highlighting a total combined project value of $23.6 billion, showing potential economic via","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/04/3126444/0/en/TMC-Releases-Two-Economic-Studies-with-Combined-NPV-of-23-6B-and-Declares-World-First-Nodule-Reserves.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","TRS","IRR","NPV","BK4100","LU0128526141.USD","TV","TMC","CCZ","BK4195","PFS","BK4211","BK4563","BK4168","BK4126"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":118,"code":"91000000","status":"200"}]}}